June 2020

OliX Pharmaceuticals signs agreement with LGC to accelerate production of asymmetric siRNA for the treatment of Sub-Retinal Fibrosis and Wet Macular Degeneration

OliX Pharmaceuticals, Inc. (KOSDAQ: 226950), a leading developer of RNAi therapeutics, has announced an exclusive contract with LGC Biosearch Technologies Inc. (LGC), a contract development and manufacturing organisation (CDMO) and part of the global life sciences tools company headquartered in London, to scale production of OliX’s OLX301D therapeutic candidate.

Under the terms of the agreement, LGC will produce the active pharmaceutical ingredients for the preclinical and clinical study of OLX301D programme, for the treatment of sub-retinal fibrosis and wet macular degeneration.

The OLX301D programme is a first-in-class treatment which may treat choroidal neovascularisation and subretinal fibrosis in patients with wet macular degeneration. Subretinal fibrosis is caused by the development of disciform scar and fibrosis underneath the retina which can cause vision loss through macular edema and detachment. Wet macular degeneration is a chronic eye disorder that causes blurred vision or a blind spot in your visual field. It's generally caused by abnormal blood vessels that leak fluid or blood into the macula.

“We are excited to collaborate with LGC as our long-term partners to scale up production of API for the OLX301D program,” said Dong Ki Lee, Ph.D., founder and Chief Executive Officer of OliX. “LGC’s deep industry expertise and global presence, along with its high-quality global facilities and standards, align with OliX’s mission to deliver innovative therapies to fulfil unmet medical needs around the world.”

David Griffiths, Ph.D., Managing Director of LGC’s Drug Development Solutions business said, “LGC is delighted to have been selected as OliX’s partner.  OLX301D is an exciting and innovative therapy that offers hope for millions of patients around the world.  As a specialist in this field, we are glad to apply our therapeutic oligonucleotide knowledge and capabilities to help OliX progress its mission which strongly aligns with LGC’s core purpose of science for a safer world”.